Catalyst Event
Innovent Biologics Inc (1801) · Earnings Release
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
4/29/2026, 12:00:00 AM
Announced Q1 2026 product revenue exceeded RMB 3.8 billion, a year-over-year increase of over 50%, driven by strong performance of its oncology and general biomedicine portfolios. The stock rose over 4.5% on the news.
Korean Translation
2026년 1분기 제품 매출이 전년 동기 대비 50% 이상 증가한 38억 위안을 초과했다고 발표함. 이는 종양학 및 일반 바이오의약품 포트폴리오의 강력한 실적에 기인하며, 해당 소식에 주가는 4.5% 이상 상승함.
Related Recent Events
Samchundang Pharm Co Ltd (000250) · Other
Extraordinary shareholders' meeting to appoint a former Financial Supervisory Service (FSS) official as a new outside director on June 30, 2026. Low importance is estimated as board changes typically have minimal immediate price impact, scheduled.
6/30/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Earnings Release
The company's quarterly earnings report is scheduled for May 18, 2026; a 5-10% price impact is estimated based on historical volatility, scheduled.
5/18/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Earnings Release
Q1 2026 earnings release on May 18, 2026. Low importance is estimated as the announcement of the release date itself usually results in minimal price movement, scheduled.
5/18/2026, 12:00:00 AM
Celltrion Inc (068270) · Earnings Release
Celltrion is scheduled to announce its Q1 2026 earnings on May 8, 2026. Analysts forecast consolidated sales of approximately 1.12 trillion KRW and an operating profit of around 314 billion KRW, which is estimated to have a medium market impact (≥5%) scheduled.
5/8/2026, 12:00:00 AM
Samsung Biologics Co Ltd (207940) · Other
The company's labor union has threatened its first-ever general strike to begin on May 1, 2026, following the breakdown of wage negotiations. Analysts forecast a price impact of over 10% due to significant operational risks, expected.
5/1/2026, 12:00:00 AM
Celltrion Inc (068270) · Other
Celltrion applied for marketing authorization to the European Medicines Agency (EMA) for 'Herzuma SC', a subcutaneous formulation of its breast cancer biosimilar Trastuzumab, on April 30, 2026. This first-in-class formulation is estimated to have a high market impact (≥10%) due to its significant competitive advantage.
4/30/2026, 12:00:00 AM